A rare case of eptifibatide-induced thrombocytopenia

Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains uncl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamar, Khalil, MacDougall, Kira, Alsheikh, Mira, Parylo, Sara, Skaradinskiy, Yevgeniy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043518/
https://www.ncbi.nlm.nih.gov/pubmed/33889336
http://dx.doi.org/10.1080/20009666.2021.1871802
Descripción
Sumario:Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.

Ejemplares similares